Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment

被引：47

作者：

Bastiancich, Chiara ^{[1
,3
]}

Bozzato, Elia ^{[1
]}

Luyten, Urszula ^{[1
]}

Danhier, Fabienne ^{[1
]}

Bastiat, Guillaume ^{[2
]}

Preat, Veronique ^{[1
]}

机构：

[1] Catholic Univ Louvain, Adv Drug Delivery & Biomat, Louvain Drug Res Inst, Ave Mounier 73,B1 73-12, B-1200 Brussels, Belgium

[2] UBL, CNRS, Micro & Nanomed Translat MINT, INSERM,UNIV Angers,U1066,UMR 6021, Angers, France

[3] Aix Marseille Univ, CNRS, Inst Neurophysiopathol, INP, Marseille, France

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2019年 / 559卷

关键词：

Gemcitabine; Paclitaxel; Hydrogel; Nanomedicine; Glioblastoma; Local delivery; LIPID NANOCAPSULES; LOCAL CHEMOTHERAPY; PACLITAXEL; GEMCITABINE; DELIVERY; ANTICANCER; CHEMORESISTANCE; TEMOZOLOMIDE; MECHANISMS; SURVIVAL;

D O I：

10.1016/j.ijpharm.2019.01.042

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Lauroyl-gemcitabine lipid nanocapsules (GemC(12)-LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. We hypothesized that GemC(12)-LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC(12)-LNC formulation was evaluated in terms of physicochemical and mechanical properties. The PTX-GemC(12)-LNC hydrogel stability and drug release were evaluated over time showing no significant differences compared to GemC(12)-LNC. The drug combination was evaluated on several GBM cell lines showing increased cytotoxic activity compared to the original formulation and synergy between PTX and GemC(12). Our results suggest that GemC(12)-LNC hydrogel can be used as nanodelivery platform for dual drug delivery to encapsulate active agents with different mechanisms of action to achieve a better antitumor efficacy against GBM or other solid tumors.

引用

页码：220 / 227

页数：8

共 40 条

[31] Mechanisms of chemoresistance to alkylating agents in malignant glioma [J].

Sarkaria, Jann N. ;

Kitange, Gaspar J. ;

James, C. David ;

Plummer, Ruth ;

Calvert, Hilary ;

Weller, Michael ;

Wick, Wolfgang .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :2900-2908

[32] Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging [J].

Schleich, N. ;

Sibret, P. ;

Danhier, P. ;

Ucakar, B. ;

Laurent, S. ;

Muller, R. N. ;

Jerome, C. ;

Gallez, B. ;

Preat, V. ;

Danhier, F. .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 447 (1-2) :94-101

[33] Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial [J].

Stupp, Roger ;

Taillibert, Sophie ;

Kanner, Andrew ;

Read, William ;

Steinberg, David M. ;

Lhermitte, Benoit ;

Toms, Steven ;

Idbaih, Ahmed ;

Ahluwalia, Manmeet S. ;

Fink, Karen ;

Di Meco, Francesco ;

Lieberman, Frank ;

Zhu, Jay-Jiguang ;

Stragliotto, Giuseppe ;

Tran, David D. ;

Brem, Steven ;

Hottinger, Andreas F. ;

Kirson, Eilon D. ;

Lavy-Shahaf, Gitit ;

Weinberg, Uri ;

Kim, Chae-Yong ;

Paek, Sun-Ha ;

Nicholas, Garth ;

Burna, Jordi ;

Hirte, Hal ;

Weller, Michael ;

Palti, Yoram ;

Hegi, Monika ;

Ram, Zvi .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (23) :2306-2316

[34] Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [J].

Stupp, Roger ;

Hegi, Monika E. ;

Mason, Warren P. ;

van den Bent, Martin J. ;

Taphoorn, Martin J. B. ;

Janzer, Robert C. ;

Ludwin, Samuel K. ;

Allgeier, Anouk ;

Fisher, Barbara ;

Belanger, Karl ;

Hau, Peter ;

Brandes, Alba A. ;

Gijtenbeek, Johanna ;

Marosi, Christine ;

Vecht, Charles J. ;

Mokhtari, Karima ;

Wesseling, Pieter ;

Villa, Salvador ;

Eisenhauer, Elizabeth ;

Gorlia, Thierry ;

Weller, Michael ;

Lacombe, Denis ;

Cairncross, J. Gregory ;

Mirimanoff, Rene-Olivier .

LANCET ONCOLOGY, 2009, 10 (05) :459-466

[35] Degradation of paclitaxel and related compounds in aqueous solutions II: Nonepimerization degradation under neutral to basic pH conditions [J].

Tian, Jiaher ;

Stella, Valentino J. .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (08) :3100-3108

[36] A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats Laboratory investigation [J].

Tyler, Betty ;

Fowers, Kirk D. ;

Li, Khan W. ;

Recinos, Violette Renard ;

Caplan, Justin M. ;

Hdeib, Alia ;

Grossman, Rachel ;

Basaldella, Luca ;

Bekelis, Kimon ;

Pradilla, Gustavo ;

Legnani, Federico ;

Brem, Henry .

JOURNAL OF NEUROSURGERY, 2010, 113 (02) :210-217

[37] In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy [J].

Vinchon-Petit, Sandrine ;

Jarnet, Delphine ;

Paillard, Archibald ;

Benoit, Jean-Pierre ;

Garcion, Emmanuel ;

Menei, Philippe .

JOURNAL OF NEURO-ONCOLOGY, 2010, 97 (02) :195-205

[38]

Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79

[39] Post-resection treatment of glioblastoma with an injectable nanomedicine-loaded photopolymerizable hydrogel induces long-term survival [J].

Zhao, Mengnan ;

Danhier, Fabienne ;

Bastiancich, Chiara ;

Joudiou, Nicolas ;

Ganipineni, Lakshmi Pallavi ;

Tsakiris, Nikolaos ;

Gallez, Bernard ;

des Rieux, Anne ;

Jankovski, Aleksandar ;

Bianco, John ;

Preat, Veronique .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 548 (01) :522-529

[40] A protocol for rheological characterization of hydrogels for tissue engineering strategies [J].

Zuidema, Jonathan M. ;

Rivet, Christopher J. ;

Gilbert, Ryan J. ;

Morrison, Faith A. .

JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS, 2014, 102 (05) :1063-1073

← 1 2 3 4 →